secwatch / observer
8-K filed November 6, 2023, 6:59 PM ET ticker TCMD CIK 0001027838
earnings confidence high sentiment positive materiality 0.70

Tactile Medical Q3 revenue $69.6M (+7% YoY); net income $22.3M vs loss; updates FY guidance

TACTILE SYSTEMS TECHNOLOGY INC

2023-Q3 EPS reported $0.88 revenue$196,771,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

TACTILE SYSTEMS TECHNOLOGY INC reported third quarter ended September 30, 2023 results: revenue $69.6 million, net income $22.3 million, EPS $0.94 per diluted share. Guidance reaffirmed.

Period
third quarter ended September 30, 2023
Revenue
$69.6 million
Net income
$22.3 million
EPS
$0.94 per diluted share
Guidance
reaffirmed
Result
reported results
Exact text from the filing
with chronic disorders , today reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Summary: ● Revenue increased 7% year-over-year to $69.6 million, compared to $65.3 million in third quarter 2022 ● Lymphedema revenue increased 15% ● Airway clearance revenue decreased 36% ● Operating income of $8.0 million, compared to
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.97

TACTILE SYSTEMS TECHNOLOGY INC reported nine months ended September 30, 2023 results: revenue $196.8 million, net income $20.3 million, EPS $0.88 per diluted share.

Period
nine months ended September 30, 2023
Revenue
$196.8 million
Net income
$20.3 million
EPS
$0.88 per diluted share
Result
reported results
Exact text from the filing
Total revenue for the nine months ended September 30, 2023, increased $23.9 million, or 13.8%, to $196.8 million
View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

TACTILE SYSTEMS TECHNOLOGY INC filing history →

Source: SEC EDGAR
accession 0001558370-23-017786
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.